APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT04785196
- Locations
- 🇨🇳
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04674514
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Beijing Chao-yang Hospital of Capital Medical University, Beijing, Beijing, China
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04643405
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04568265
- Locations
- 🇨🇳
Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 284
- Registration Number
- NCT04501120
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guandong, China
🇨🇳Henan Tumor Hospital, Zhengzhou, Henan, China
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
- Conditions
- Interventions
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT04496349
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸City of Hope, Duarte, California, United States
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04494503
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT04358393
- Locations
- 🇺🇸
Texas Oncology - Tyler, Tyler, Texas, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Registration Number
- NCT04354727
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04284488
- Locations
- 🇨🇳
Sun-Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The Affiliated Hospital OF Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Foshan First People's Hospital, Foshan, Guangdong, China